PHIBRO ANIMAL HEALTH CORP (PAHC) stock intrinsic value fair value estimate & owner earnings analysis

Phibro Animal Health sells products that keep farm and companion animals healthy and productive. About three-quarters of its $1.52 billion of fiscal 2026 sales (year ended June 30, 2026) came from Animal Health: medicated feed additives such as antibacterials and anticoccidials, nutritional specialty products, and poultry and livestock vaccines. The rest comes from Mineral Nutrition (trace minerals such as copper and zinc, $282 million) and Performance Products (ingredients for personal care and industrial uses, $74 million). On October 31, 2024 Phibro bought Zoetis's medicated feed additive portfolio for about $298 million, paid entirely with new bank loans. That deal roughly doubled the company's borrowings and makes fiscal 2026 the first full year of the enlarged business. How we measured earning power. We start from operating cash flow, strip out swings in inventory, receivables and payables, subtract stock-based pay, and subtract the capital spending needed to maintain the existing plants. Because the company now carries substantial debt, we measure this cash before interest, value the whole business, and then subtract what it owes. In fiscal 2026 that cash before interest came to about $154 million, or $3.75 per share. Fiscal 2025 came to about $105 million, or $2.58 per share, but that year held only eight months of the acquired products and about $13 million of one-time deal costs; adjusted for those, it would have been roughly $3.30. We use $3.45 per share (about $141 million a year) as the normal level. It deliberately sits below fiscal 2026 because part of that year's 2.3-point gross margin gain came from price increases and product mix that have not yet been tested through a weak livestock year, while currency losses in Israel, Argentina and Brazil recur almost every year. Six straight quarters of steady profits since early 2025 support a level in this range. Fiscal 2026 operating cash flow was unusually low, at $69 million, because the company built $86 million of inventory ahead of expected tariffs and to supply the acquired product lines. We treated that as a timing effect, not a drop in earning power. We did not use fiscal 2024 or the years before the acquisition to set the level, because they describe a smaller business. Amortization of acquired intangibles is modest (about $7 million a year), and we account for it through the slow fade built into every case rather than by lowering the starting level. Growth. Cash earnings per share rose 45% in fiscal 2026, but almost all of that came from owning the acquired products for a full year, so it will not repeat. The base case assumes 1.5% growth in the first year and for the following decade. Phibro's sales grew about 3.5% a year from fiscal 2015 to fiscal 2024, through the 2020 downturn, but its cash earnings did not keep pace, so we credit less than half that rate. We give no credit for synergy targets, new products, the company's cost program or management's growth plans. After year 10, the base case holds earnings flat for twenty years and then fades them to zero over the following decade. What keeps them going is decades-old product registrations, manufacturing plants and customer relationships. The fade reflects steady regulatory pressure on antibiotic use in animal feed. Debt. At June 30, 2026 Phibro owed $737.9 million: term loans maturing in July 2029 and July 2031, plus $116 million drawn on a revolving credit line that also matures in July 2029. It held $82 million of cash and short-term investments. We treat about $42 million of that as surplus, because the rest is needed to run operations in many countries. That leaves net debt of about $696 million, or $16.99 per share. The loans carry floating rates of roughly 6 to 6.4%, and the company's projected interest for fiscal 2027 is $43.8 million. That is close to our 6% discount rate, so we made no further adjustment for the cost of the debt. Net debt runs about 3 times annual operating earnings before depreciation, and nothing in the filings points to trouble refinancing the 2029 maturities. Base case. Normal cash earnings of $3.45 per share grow 1.5% a year. Mecadox (carbadox), a swine product with about $21 million of sales, is withdrawn in the fifth year. The FDA has proposed withdrawing its approval since November 2023, Phibro is challenging that in court, and the product has survived regulatory attempts since 2016. On these assumptions the business is worth about $2.20 billion, or $53.73 per share. It owes a net $696 million, which leaves about $1.51 billion, or $36.74 per share, for shareholders. Bear case. The fiscal 2026 margin gains largely reverse, putting normal earnings at $2.85 per share. Mecadox is lost in the second year. Continuing regulatory erosion of feed antibiotics and the shrinking personal-care ingredients business (down 8% in fiscal 2026) cut earnings 1% a year for fifteen years, and then earnings fade to zero over the next fifteen. The business would be worth about $1.20 billion, or $29.33 per share. Less the $696 million owed, that leaves $505 million, or $12.34 per share. Even here, cash before interest of roughly $115 million a year covers the interest bill about 2.6 times, so the debt stays serviceable. Bull case. Fiscal 2026's $3.75 per share holds as the normal level and Mecadox survives. Price increases of the kind achieved in fiscal 2026, plus continued double-digit growth in vaccines (up 14% in fiscal 2026, driven by poultry in Latin America), lift earnings 3% a year for ten years. Earnings then hold flat for twenty-five years and fade over the following decade. The business would be worth about $2.89 billion, or $70.51 per share. After the $696 million of net debt, that leaves $2.19 billion, or $53.52 per share. What changed since our previous estimate. Our earlier estimates of about $35, $58 and $76 per share valued the cash left after interest as if today's loans would be rolled over forever on today's terms, and they never subtracted the $696 million the company owes. We now value the business before its lenders, then deduct the debt in full. That lowers every case by about $17 per share. We also dropped the earlier assumption of low-single-digit growth continuing forever: the new cases end in a fade rather than growing indefinitely. Partly offsetting those changes, the starting level is higher, because we now weight the full-year results of the combined business more heavily than the partial fiscal 2025. Other points. In August 2026 management decided to close its Chicago Heights, Illinois plant by summer 2027 and move production elsewhere. The costs are not yet estimated and are not in our figures. Phibro has two classes of shares, and an entity controlled by the Bendheim family holds about 90% of the votes, so outside shareholders have little say. Given the debt, the regulatory exposure of feed antibiotics, and exposure to Latin American currencies and livestock cycles, the estimate calls for a wide margin of safety. The margin-of-safety price is about $20 per share.